Cargando…

Correlation between pathologic complete response, event-free survival/disease-free survival and overall survival in neoadjuvant and/or adjuvant HR+/HER2-breast cancer

PURPOSE: The study’s purpose was to evaluate the correlation between overall survival (OS) and its potential surrogate endpoints: pathologic complete response (pCR) and event-free survival (EFS)/disease-free survival (DFS) in neoadjuvant and/or adjuvant HR+/HER2- breast cancer. METHODS: Systematic s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gogate, Anagha, Ranjan, Sandip, Kumar, Amit, Bhandari, Hitesh, Papademetriou, Eros, Kim, Inkyu, Potluri, Ravi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10185900/ https://www.ncbi.nlm.nih.gov/pubmed/37205193 http://dx.doi.org/10.3389/fonc.2023.1119102

Ejemplares similares

Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2− metastatic breast cancer
por: Forsythe, Anna, et al.
Publicado: (2018)

Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2− metastatic breast cancer?
por: Forsythe, Anna, et al.
Publicado: (2018)

Evaluating relapse-free survival as an endpoint for overall survival in adjuvant immunotherapy trials
por: Li, Yuanfang, et al.
Publicado: (2023)

A study on comparison of overall survival and disease- free survival among gastric cancer patients treated with two adjuvant and neoadjuvant methods
por: Saadati, K, et al.
Publicado: (2015)

A gene expression signature in HER2+ breast cancer patients related to neoadjuvant chemotherapy resistance, overall survival, and disease-free survival
por: Barrón-Gallardo, Carlos A., et al.
Publicado: (2022)

Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma
por: Liu, Hua, et al.
Publicado: (2022)

Neoadjuvant chemotherapy response, disease-free survival, and overall survival of breast cancer in a single institution
por: Prihantono, et al.
Publicado: (2023)

Neoadjuvant chemotherapy for borderline resectable and upfront resectable pancreatic cancer increasing overall survival and disease-free survival?
por: Fossaert, Violette, et al.
Publicado: (2022)

Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer
por: Gallagher, Christopher M., et al.
Publicado: (2016)

Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial
por: Dieci, Maria Vittoria, et al.
Publicado: (2023)

Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients
por: Chen, I-Chun, et al.
Publicado: (2021)

Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review
por: Reinert, Tomás, et al.
Publicado: (2017)

Progression-free or overall survival…revisited in BOLERO-2
por: Gupta, Sudeep
Publicado: (2014)

Ribociclib Improves Overall Survival in HR+/HER2– Metastatic Breast Cancer Across Common Genomic and Clinical Subtypes
por: Jacobson, Anne
Publicado: (2022)

Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2022)

Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer
por: Beauchemin, Catherine, et al.
Publicado: (2014)

Overall survival and disease-free survival in endometrial cancer: prognostic factors in 276 patients
por: Tejerizo-García, Álvaro, et al.
Publicado: (2013)

Prognostic Factors of Atypical Meningioma: Overall Survival Rate and Progression Free Survival Rate
por: Lee, Jae Ho, et al.
Publicado: (2017)

The prediction models for postoperative overall survival and disease‐free survival in patients with breast cancer
por: Shigemizu, Daichi, et al.
Publicado: (2017)

Prognostic Factors Affecting Disease-Free Survival and Overall Survival in T4 Colon Cancer
por: Eom, Taeyeong, et al.
Publicado: (2021)

Author Correction: Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial
por: Dieci, Maria Vittoria, et al.
Publicado: (2023)

Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials
por: Lerebours, Florence, et al.
Publicado: (2020)

Nomograms to Predict the Disease-free Survival and Overall Survival after Radiofrequency Ablation for Hepatocellular Carcinoma
por: Takuma, Yoshitaka, et al.
Publicado: (2017)

Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer
por: Cicero, Giuseppe, et al.
Publicado: (2018)

Radiofrequency ablation of hepatocellular carcinoma: a meta-analysis of overall survival and recurrence-free survival
por: Gardini, Andrea Casadei, et al.
Publicado: (2018)

Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer
por: Varkaris, Andreas, et al.
Publicado: (2019)

MRPL27 contributes to unfavorable overall survival and disease-free survival from cholangiocarcinoma patients
por: Zhuang, Liping, et al.
Publicado: (2021)

A Novel Nomogram Model to Predict the Recurrence-Free Survival and Overall Survival of Hepatocellular Carcinoma
por: Zhang, Shu-Wen, et al.
Publicado: (2022)

A Systematic Review on Overall Survival and Disease-Free Survival Following Total Pelvic Exenteration
por: Miri, Seyed Rouhollah, et al.
Publicado: (2022)

Erratum to “Prognostic factors affecting disease-free survival and overall survival in T4 colon cancer”
Publicado: (2023)

Disease-free survival as a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a meta-analysis of 20 randomized controlled trials
por: Nie, Run-Cong, et al.
Publicado: (2020)

Abemaciclib plus fulvestrant in East Asian women with HR+, HER2− advanced breast cancer: Overall survival from MONARCH 2
por: Toi, Masakazu, et al.
Publicado: (2022)

Interpretation of meta-analysis evaluating progression-free survival as a surrogate endpoint for overall survival in glioblastoma
por: Han, Kelong, et al.
Publicado: (2015)

Quantifying the association between progression‐free survival and overall survival in oncology trials using Kendall's τ
por: Weber, Enya M., et al.
Publicado: (2018)

Systematic Review and Meta-Analysis of Correlation of Progression-Free Survival-2 and Overall Survival in Solid Tumors
por: Chowdhury, Simon, et al.
Publicado: (2020)

Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review
por: Belin, Lisa, et al.
Publicado: (2020)

Sarcopenia is associated with worse surgical complications but not relapse-free survival and overall survival in patients with retroperitoneal liposarcoma
por: Zhao, Mingkun, et al.
Publicado: (2022)

Correlation of Anticancer Drug Prices with Outcomes of Overall Survival and Progression-Free Survival in Clinical Trials in Japan
por: Okabe, Ayano, et al.
Publicado: (2023)

Accidental Morcellation of Uterine Leiomyosarcoma Influences Relapse Free Survival but Does Not Negatively Influence Overall Survival
por: Reichert, Verena M. C., et al.
Publicado: (2023)

Prognostic nomogram that predicts progression-free survival and overall survival of patients with ovarian clear cell carcinoma
por: Li, Jiayi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1j33ts01qevnjerdi4pn3t1o1u